<DOC>
	<DOCNO>NCT01333293</DOCNO>
	<brief_summary>Patients mastocytosis often suffer associate symptom nausea , vertigo , fatigue , urticaria , abdominal cramp , diarrhea hypotension due release mediator mast cell . These patient also increase frequency anaphylactic/anaphylactoid reaction due allergen hymenoptera nonspecific stimulus contrast medium , local anesthetic analgesic . In addition , increase osteoporosis mastocytosis patient due activity mast cell mediator osteoblasts osteoclast . Symptoms mastocytosis respond poorly treatment antihistamine antiallergic drug . There currently specific treatment disease exception rare case . There , however , case report suggest omalizumab might decrease symptom include hypotensive event . The aim study investigate whether patient suffer mastocytosis benefit 6 month course omalizumab regard symptom quality life whether applied vitro vivo monitoring tool represent useful surrogate marker efficacy omalizumab patient mastocytosis . - Trial medicinal product</brief_summary>
	<brief_title>The Effect Xolair Â® ( Omalizumab ) Mastocytosis Patients</brief_title>
	<detailed_description>The study take place double-blind placebo control study . After first run-period 2 month participant randomization ( 1:1 ) two group take place : Group A : With omalizumab treatment 6 month ; dosage administration schedule accord body weight total IgE level ( 1/2 patient ) . Group B : Placebo ( 1/2 patient ) . After 4 month treatment group patient encourage stop drug give reduce mast cell related effect , mainly antihistaminics . In case disturb symptom reoccurring patient allow restart drug . The evaluation take place 5 month treatment . Finally , follow visit 1 4 month study take place .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion criterion : Histological proven mastocytosis ( cutaneous systemic ) ; Diagnosis make one marrow unction and/or skin biopsy histological work ; Age : 1870 year Exclusion criterion Age &lt; 18 year ; Known hypersensitivity omalizumab component ; History cancer previous 5 year ; Patients serious infection ; Patients active tuberculosis undergo antiTB therapy ; Patients currently treat systemic immunosuppressive agent ; Female patient pregnant breast feeding ; Contraception must perform save reliable accept method oral implanted contraceptive , intravaginal male preservative permanent method tubal ligation . Patients know positivity human immunodeficiency virus ( HIV ) . HIV screen perform HIV 1/2 Antibodydetection test . Note : Specific immunotherapy insect sting allergy exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>mastocytosis</keyword>
	<keyword>omalizumab</keyword>
</DOC>